Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Keratoderma, Palmoplantar, Epidermolytic

ClinicalTrials.gov lists 9 trials for Keratoderma, Palmoplantar, Epidermolytic or a narrower condition beneath it.

MeSH D053546 Congenital / Hereditary / Neonatal C16 C17
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 3 Phase 3 2 Not applicable Not applicable 4 Observational Observational 3 Phase 3 Phase 3 2 Not applicable Not applicable 4 Observational Observational 3

Trials per phase

9 of the 9 trials are tagged with Keratoderma, Palmoplantar, Epidermolytic itself; the rest are tagged with a narrower condition beneath it.

Get the Keratoderma, Palmoplantar, Epidermolytic report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Keratoderma, Palmoplantar, Epidermolytic trials start? (8)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 3
  • Not applicable
  • Observational

Top of scale: 2

2010: 1 trials (Phase 3 1) 2011: 1 trials (Phase 3 1) 2015: 1 trials (Observational 1) 2018: 1 trials (Not applicable 1) 2020: 2 trials (Observational 1, Not applicable 1) 2022: 1 trials (Not applicable 1) 2023: 1 trials (Observational 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 1
2023 1
2022 1
2020 2
2018 1
2015 1
2011 1
2010 1

No forecast is made for this condition: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.

Recruitment duration, a model prediction: none of the 9 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Keratoderma, Palmoplantar, Epidermolytic trials in? (3)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 3 2
Not applicable 4
Observational 3

How many Keratoderma, Palmoplantar, Epidermolytic trials are recruiting? (3)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 1
Recruiting 2
Completed 6

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Keratoderma, Palmoplantar, Epidermolytic trials? (4)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Pfizer 2
Proteocyte Diagnostics Inc. 2
Candela Corporation 1
Mirka Ltd 1

Which serious adverse events do Keratoderma, Palmoplantar, Epidermolytic trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Coronary artery disease (unrelated) 2 1
Osteoarthritis (unrelated) 2 1
Pulmonary embolism (unrelated) 2 2
Acute myocardial infarction (unrelated) 1 1
Anaemia (unrelated) 1 1

Prevalence (2)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Epidermolytic palmoplantar keratoderma Point prevalence 1-9 / 100 000 Ireland Not stated Exact
Epidermolytic palmoplantar keratoderma Point prevalence 1-9 / 100 000 Ireland Not stated Exact

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Epidermolytic palmoplantar keratoderma 2199 Exact Orphanet Rare Disease Ontology (ORDO)
Epidermolytic palmoplantar keratoderma 2199 Exact Orphadata Science knowledge files, Product 1

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: publications and sub-conditions in mesh.

Not computed for conditions with fewer than 10 trials: drugs tested.

Browse all condition evidence pages